BMS-354825: A novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia

Expert Opinion on Investigational Drugs

Volumn 14, Issue 1, 2005, Pages 89-91

  Doggrell, Sheila A ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Doggrell Biomedical Communications   (New Zealand)

Author keywords

BCR ABL mutants; BMS 354825; Chronic myeloid leukaemia; ECE; Imatinib

Indexed keywords

6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; 6 (2,6 DICHLOROPHENYL) 2 [3 (HYDROXYMETHYL)ANILINO] 8 METHYLPYRIDO[2,3 D]PYRIMIDIN 7(8H) ONE; [4 [2 CYCLOPENTYL 9 (3 HYDROXYPHENETHYL)PURIN 6 YLAMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE; ALPHA INTERFERON; ANTILEUKEMIC AGENT; BCR ABL PROTEIN; CYTARABINE; DASATINIB; IMATINIB; NEW DRUG; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER RELAPSE; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG BINDING; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; GENE MUTATION; HUMAN; IMMUNE DEFICIENCY; MUTANT; NONHUMAN; OUTCOMES RESEARCH; SIDE EFFECT; WILD TYPE;

ANIMALS; DRUG RESISTANCE, NEOPLASM; DRUGS, INVESTIGATIONAL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MICE; PIPERAZINES; PYRIMIDINES; THIAZOLES;

EID: 12744275046     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.1.89     Document Type: Article

References (12)

1. SHAH NP, TRAN C, LEE FY et al.: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (2004) 305 399-401.
2. DRUKER BJ, TALPAZ M: RESTA DJ et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. (2001) 344:1031-1037.
3. MARIND, MARKTEL S, SZYDLO R et al.: Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon α. Lancet (2003) 362:617-619.
4. DRUKER BJ, SAWYERS CL, KANTARJIAN H et al.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase blast crisis of chronic myeloid leukemia and acute lymphoblast leukemia with the Philadelphia chromosome. N. Engl. J. Med. (2001) 344 1038-1042
5. O'BRIEN SG, GUILHOT F, LARSON RA et al.: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. (2003) 348:994-1004.
6. HAHN EA, GLENDENNING GA, SORENSEN MV et al.: Quality of life in patients with newly diagnosed chronic phase myeloid leukemia on imatinib versus interferon α plus low-dose cytarabine: results from the IRIS study. J. Clin. Oncol. (2003) 21:2138-2146.
7. ANSTROM KJ, REED SD, ALLEN AS, GLENDENNING GA, SCHULMAN KA: Long term survival estimates for imatinib versus interferon-α plus low-dose cytarabine for patients with newly diagnosed chronic phase chronic myeloid leukemia. Cancer (2004) 101(11):2584-2592.
8. DEININGER MW, DRUKER BJ: SRCircumventing imatinib resistance. Cancer Cell (2004) 6:108-110.
9. SHAH NP, NICOLL JM, NAGAR B et al.: Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell (2002) 2:117-125.
10. LA ROSEE P, CORBIN AS, STOFFREGEN EP, DEININGER MW, DRUKER BJ: Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI551). Cancer Res. (2002) 62:7149-7153.
11. HURRON DR, GORRE ME, KRAKER AJ et al.: A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of BCR-ABL-driven K562 cells and is effective against resistant Bcr-abl mutants. Clin. Cancer Res. (2003) 9:1267-1273.
12. O'HARE T, POLLOCK R, STOFFREGEN EP et al.: Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood (2004) 104 2532-2539.